Novo Nordisk and Valo Health have expanded their AI collaboration to a potential value of over $4.6 billion, aiming to develop up to 20 treatments for obesity, type 2 diabetes, and cardiovascular disease. This marks a significant increase from their initial partnership, which focused on 11 programs. The agreement includes a $190 million upfront payment and emphasizes the use of Valo's Opal Computational Platform to enhance drug discovery through human data insights.